drugset / Trial / NCT00902525
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
Phase 2
Terminated
25 enrolled
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte · collab
NaSingle-groupOpen-labelTreatment
Summary
Despite of the availability of treatment for this disease, this study is justified because no known therapies are really curative and it is necessary to look for new treatment options to improve the clinical outcome and prognosis of relapsed aggressive lymphoma. This study is designed for patients not eligible for high-dose chemotherapy and autologous stem cells transplantation.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-01
- Completion
- 2011-09
Outcome
Outcome not reported
Stopped (Enrollment): “After enrolling 25 patients an interim analysis was done.The study was discontinued in the absence of the minimum number of 6 patients free of events”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 90Y-ibritumomab tiuxetan | Other / unclassified | 7.4 mbq/kg | — |